Cargando…
Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity
BACKGROUND: Continuous infusion of doxorubicin has been a strategy to reduce cardiotoxicity. Epirubicin is another anthracycline in common clinical use. However, evidence is lacking regarding whether this strategy can reduce cardiotoxicity of epirubicin without compromising antineoplastic efficacy....
Autores principales: | Yang, Fang, Lei, Qiao, Li, Lu, He, Jian Chang, Zeng, Jiajia, Luo, Chunxiang, Yeung, Sai-Ching Jim, Yang, Runxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683617/ https://www.ncbi.nlm.nih.gov/pubmed/29131861 http://dx.doi.org/10.1371/journal.pone.0188025 |
Ejemplares similares
-
Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023) -
Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant
por: Yamasaki, Miho, et al.
Publicado: (2019) -
A Hydrogel-Based Epirubicin Delivery System for Intravesical Chemotherapy
por: Liu, Ching-Wen, et al.
Publicado: (2016) -
Preventing effect of astragalus polysaccharide on cardiotoxicity induced by chemotherapy of epirubicin: A pilot study
por: Li, Xiaofang, et al.
Publicado: (2022) -
Clinical Application of the Heart Rate Deceleration Capacity Test to Predict Epirubicin-induced Cardiotoxicity
por: Feng, Yan-ying, et al.
Publicado: (2015)